Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JUSTIN A REYNOLDS

Allopathic & Osteopathic Physicians Internal Medicine Transplant Hepatology

NPI
1568642353
CMS profile
116427
Location
PEORIA, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$68,957.11

122 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 122 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JUSTIN A REYNOLDS

NPI 1568642353 · CMS profile ID 116427

Allopathic & Osteopathic Physicians / Internal Medicine / Transplant Hepatology

PEORIA, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 122 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1568642353?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JUSTIN A REYNOLDS, NPI 1568642353, CMS profile ID 116427. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 122 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568642353?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JUSTIN A REYNOLDS, NPI 1568642353, CMS profile ID 116427. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 122 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568642353?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JUSTIN A REYNOLDS, NPI 1568642353, CMS profile ID 116427, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 122 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1568642353?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

122 matching records · $68,957.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 122 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 122.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Madrigal Pharmaceuticals $77.3909/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144180143 CMS
Madrigal Pharmaceuticals $94.6209/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144180145 CMS
Madrigal Pharmaceuticals $81.4409/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144180147 CMS
Madrigal Pharmaceuticals $42.3009/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144180149 CMS
Gilead Sciences, Inc. $27.7209/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133828713 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $24.7209/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153673902 CMS
Gilead Sciences, Inc. $3,240.0009/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133608410 CMS
Madrigal Pharmaceuticals $42.2609/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144180115 CMS
Madrigal Pharmaceuticals $139.5409/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144180117 CMS
Madrigal Pharmaceuticals $4,583.0009/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144180119 CMS
Madrigal Pharmaceuticals $195.3309/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144180121 CMS
Madrigal Pharmaceuticals $364.9609/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144180123 CMS
Madrigal Pharmaceuticals $2,115.0009/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144180125 CMS
Madrigal Pharmaceuticals $18.8609/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144180127 CMS
Gilead Sciences, Inc. $5,150.0009/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133608408 CMS
Gilead Sciences, Inc. $7.7509/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133828709 CMS
Gilead Sciences, Inc. $28.7709/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133828711 CMS
Gilead Sciences, Inc. $30.0009/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133869568 CMS
Gilead Sciences, Inc. $121.9609/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133828707 CMS
Gilead Sciences, Inc. $84.5009/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133869564 CMS
Gilead Sciences, Inc. $302.8909/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133869566 CMS
Madrigal Pharmaceuticals $144.2209/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144180111 CMS
Madrigal Pharmaceuticals $3,173.0009/10/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144180113 CMS
Gilead Sciences, Inc. $31.1909/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133828705 CMS
Gilead Sciences, Inc. $16.1809/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133828703 CMS
Ipsen Biopharmaceuticals, Inc $32.3009/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091984559 CMS
Gilead Sciences, Inc. $36.8408/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133828697 CMS
Gilead Sciences, Inc. $52.2008/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133828699 CMS
Gilead Sciences, Inc. $59.3608/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133828701 CMS
Gilead Sciences, Inc. $253.4908/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133869558 CMS
Gilead Sciences, Inc. $308.9708/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133869560 CMS
Gilead Sciences, Inc. $376.3008/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133869562 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.7108/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153678708 CMS
Gilead Sciences, Inc. $600.0008/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133608406 CMS
Gilead Sciences, Inc. $19.3808/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133828695 CMS
ABBVIE INC. $32.1107/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105940934 CMS
Intercept Pharmaceuticals, Inc. $18.6407/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113636336 CMS
Ipsen Biopharmaceuticals, Inc $23.6607/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091984565 CMS
Gilead Sciences, Inc. $14.7407/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133869556 CMS
ABBVIE INC. $16.6507/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105940932 CMS
Gilead Sciences, Inc. $3,030.0007/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133608404 CMS
Gilead Sciences, Inc. $149.1807/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133828693 CMS
Gilead Sciences, Inc. $16.4507/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133828691 CMS
Gilead Sciences, Inc. $13.5606/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133828689 CMS
Gilead Sciences, Inc. $30.0506/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133828687 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $21.4405/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153726287 CMS
Intercept Pharmaceuticals, Inc. $18.6405/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113636334 CMS
Gilead Sciences, Inc. $21.7905/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133828685 CMS
Gilead Sciences, Inc. $28.1204/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133828683 CMS
Gilead Sciences, Inc. $6.5304/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133828681 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $24,654.03 51
PY2020 $8,000.00 5
PY2021 $8,045.44 20
PY2022 $16,800.13 37
PY2023 $13,699.41 34
PY2024 $68,957.11 122
PY2025 $171,401.57 193

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $81,427.29 27
PY2024 Principal investigator $188,408.52 34
PY2023 Recipient $1,843.55 17
PY2023 Principal investigator $62,881.00 20
PY2022 Principal investigator $318.00 2
PY2021 Principal investigator $40,114.46 7
PY2020 Principal investigator $84,285.41 13
PY2019 Principal investigator $166,727.36 49

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

27 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,396.50 06/13/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223269144
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,729.59 06/11/2025 Non-covered Recipient Entity
ST JOSEPHS PHOENIX
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223281064
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $115.71 06/04/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269142
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,660.00 05/21/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223269140
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,500.00 05/16/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223269136
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $665.00 05/16/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223269138
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $465.50 05/01/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269132
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $869.16 05/01/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269134
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $566.58 03/26/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269114
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,154.42 03/26/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269116
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,800.16 03/26/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269118
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $465.50 03/26/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269120
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $465.50 03/26/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269122
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $465.50 03/26/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269124
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,899.42 03/26/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269126
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $465.50 03/26/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269128
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $465.50 03/26/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269130
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,064.00 03/21/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269108
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $465.50 03/21/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223269110
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $465.50 03/21/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223269112
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $755.44 03/19/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269104
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20,615.00 03/19/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223269106
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $399.00 03/05/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223269100
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $66.50 03/05/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223269102
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,048.87 02/21/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269098
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $234.75 02/19/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269096
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $19,163.19 02/12/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269094